Mechanisms of persistent activation of the androgen receptor in CRPC: recent advances and future perspectives (Q37947091)

25 August 2017

Mechanisms of persistent activation of the androgen receptor in CRPC: recent advances and future perspectives (English)

1 reference

25 August 2017

Nagalakshmi Nadiminty

series ordinal

1

1 reference

PubMed ID

22009116

25 August 2017

Allen C Gao

series ordinal

2

1 reference

25 August 2017

19 October 2011

1 reference

25 August 2017

World Journal of Urology

1 reference

25 August 2017

30

1 reference

25 August 2017

3

1 reference

25 August 2017

287-295

1 reference

https://scigraph.springernature.com/pub.10.1007/s00345-011-0771-3

25 August 2017

0 references

cites work

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

In vivo amplification of the androgen receptor gene and progression of human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

Molecular determinants of resistance to antiandrogen therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

Androgen receptor signaling and mutations in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

The role of androgen receptor mutations in prostate cancer progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

Structural and functional consequences of glutamine tract variation in the androgen receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

Integrative genomic profiling of human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

ETS gene fusions in prostate cancer: from discovery to daily clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

The discovery and application of gene fusions in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

A causal role for ERG in neoplastic transformation of prostate epithelium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

Androgen-induced TMPRSS2:ERG fusion in nonmalignant prostate epithelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

TMPRSS2-ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

Looping versus linking: toward a model for long-distance gene activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

Going the distance: a current view of enhancer action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

Persistent intraprostatic androgen concentrations after medical castration in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

Castration-resistant prostate cancer: targeting androgen metabolic pathways in recurrent disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

Interleukin-6: minor player or starring role in the development of hormone-refractory prostate cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

Interleukin-6 regulates androgen synthesis in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

Interleukin-4 enhances prostate-specific antigen expression by activation of the androgen receptor and Akt pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

Interleukin-4 activates androgen receptor through CBP/p300.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

Requirement for NF-(kappa)B in interleukin-4-induced androgen receptor activation in prostate cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

Interleukin-4 stimulates androgen-independent growth in LNCaP human prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

Differential expression of interleukin-8 and its receptors in the neuroendocrine and non-neuroendocrine compartments of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

The interleukin-8 pathway in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

Interleukin-8 signaling promotes translational regulation of cyclin D in androgen-independent prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

Interleukin-8 signaling attenuates TRAIL- and chemotherapy-induced apoptosis through transcriptional regulation of c-FLIP in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

Chemotherapy-induced CXC-chemokine/CXC-chemokine receptor signaling in metastatic prostate cancer cells confers resistance to oxaliplatin through potentiation of nuclear factor-kappaB transcription and evasion of apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

Depletion of intrinsic expression of Interleukin-8 in prostate cancer cells causes cell cycle arrest, spontaneous apoptosis and increases the efficacy of chemotherapeutic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

Stat3 activation in prostatic carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

RNA interference targeting Stat3 inhibits growth and induces apoptosis of human prostate cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

Cross-talk between signal transducer and activator of transcription 3 and androgen receptor signaling in prostate carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

Stat3 enhances transactivation of steroid hormone receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

Stable expression of constitutively-activated STAT3 in benign prostatic epithelial cells changes their phenotype to that resembling malignant cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

B-cell-derived lymphotoxin promotes castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

Mutual transcriptional interference between RelA and androgen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

Identification of a negative regulatory cis-element in the enhancer core region of the prostate-specific antigen promoter: implications for intersection of androgen receptor and nuclear factor-kappaB signalling in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

NF-kappaB regulates androgen receptor expression and prostate cancer growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

aPKClambda/iota promotes growth of prostate cancer cells in an autocrine manner through transcriptional activation of interleukin-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

Tumour-initiating stem-like cells in human prostate cancer exhibit increased NF-κB signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

Activation of NF-{kappa}B by TMPRSS2/ERG Fusion Isoforms through Toll-Like Receptor-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

Nuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer: an immunohistochemical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

NF-kappaB2/p52 enhances androgen-independent growth of human LNCaP cells via protection from apoptotic cell death and cell cycle arrest induced by androgen-deprivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

NF-kappaB2 processing and p52 nuclear accumulation after androgenic stimulation of LNCaP prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

Aberrant activation of the androgen receptor by NF-kappaB2/p52 in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

LIGHT, a member of the TNF superfamily, activates Stat3 mediated by NIK pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

Stat3 activation of NF-{kappa}B p100 processing involves CBP/p300-mediated acetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

ANDROGEN RECEPTOR GENE AMPLIFICATION AT PRIMARY PROGRESSION PREDICTS RESPONSE TO COMBINED ANDROGEN BLOCKADE AS SECOND LINE THERAPY FOR ADVANCED PROSTATE CANCER

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0771-3

Stat3 enhances the growth of LNCaP human prostate cancer cells in intact and castrated male nude mice

21 January 2018

1 reference

12 December 2020

Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis

1 reference

12 December 2020

Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer

1 reference

12 December 2020

Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model

1 reference

12 December 2020

Cytokine disbalance in common human cancers

1 reference

12 December 2020

Interleukin-4 in patients with prostate cancer.

1 reference

12 December 2020

Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer

1 reference

12 December 2020

Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer

1 reference

12 December 2020

Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor

1 reference

12 December 2020

Microarray analysis reveals potential target genes of NF-kappaB2/p52 in LNCaP prostate cancer cells

1 reference

12 December 2020

Human prostatic carcinoma cells produce an increase in the synthesis of interleukin-6 by human osteoblasts

1 reference

12 December 2020

Interleukin-6-type cytokines stimulate mesenchymal progenitor differentiation toward the osteoblastic lineage.

1 reference

12 December 2020

Steroidogenic enzymes and stem cell markers are upregulated during androgen deprivation in prostate cancer

1 reference

12 December 2020

In situ androgen producing enzymes in human prostate cancer

1 reference

12 December 2020

A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities

1 reference

12 December 2020

Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line

1 reference

12 December 2020

10.1007/S00345-011-0771-3

Identifiers

DOI

1 reference

25 August 2017

1 reference

PubMed ID

22009116